Fredun Pharmaceuticals Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://www.stockscans.in/document/m58yxnoopuu6sba6anad8hj0.pdf

Key Takeaways


New-Age Vertical Momentum

Fredun Medhora: "I always under promise, I believe in under promising and over delivering, it's better to be conservative than be over enthusiastic."

Pet Care Ecosystem & Wagr Acquisition

Fredun Medhora: "I want people to reflect that in India right now, there is no neutral space for Pet Care. HUFT and Just Dogs and a couple of other companies are selling most of their products and pushing every time a good product sells, they brand the products themselves and push it."

Snacky Jain Launch & Demand Surprise

Fredun Medhora: "We had to go back on our drawing board and revisit our manufacturing and procurement and everything, with the kind of growth that, I mean, with the kind of order book that we have for Snacky Jain."

Manufacturing & Infrastructure


Export & Geographic Expansion


Financial Position & Capital Allocation


Guidance & Commitments

CommitmentSpecificsTimeline
PAT targetAchieve ₹90 crores PAT; may do betterFY'29
Revenue compositionRevenue fully driven by vintage genericsFY'29
Revenue compositionOver 51% of revenue from U.S. businessFY'32
Manufacturing capacityOne of the largest plants for a single location in IndiaWithin 2 years
Mobility growth25% to 30% year-on-year growthOngoing; sharp increase once more geographies added in latter half of next year
Wagr platform launchTeams launch for Wagr and online platformsMid-January to first week of February
Snacky Jain distributionIn stores across certain geographiesBy November-end
Snacky Jain nationwide reachIn most parts of the countryWithin 6 months
Snacky Jain range expansionWhole range of Jain-related products (gut health, mobility, nutrition)Next 6 months
Wagr revenue scaleA few million dollars a month, maybe more5 to 7 years
Team effects visibilityWorld will see effects of new team and interact with themWithin 24 to 36 months

Key Metrics

MetricQ2 FY26
Total income₹145.29 cr, +35% YoY
EBITDA₹22.34 cr, +60% YoY
EBITDA margin15.37%, improving from prior year
Net profit₹9.73 cr, +128% YoY
H1 FY26 total income₹265.15 cr, +42% YoY
H1 FY26 EBITDA₹39.33 cr, +61% YoY
H1 FY26 PAT₹16.50 cr, +96% YoY
Outsourced production share5% to 7% currently, expected to rise to 15% to 20% in coming years
Products manufactured~1,700 products in portfolio
Contract manufacturing locations added37 locations across India in last 24 months
Mobility business growth outlook25% to 30% anticipated YoY growth
R&D team size40 people in F&D at plant
International presence52 countries directly and indirectly
Wagr acquisition costZero, with ~80% majority stake
Wagr planned investment₹4 cr to ₹5 cr over next 18 to 24 months, with additional ₹5 cr to ₹7 cr later
FY'29 PAT guidance₹90 cr (per prior guidance, referenced on call)